Topics

FDA Grants Breakthrough Therapy Designation to Abatacept for Acute GVHD Prevention

19:00 EST 3 Dec 2019 | Cancer Networks

The FDA granted a breakthrough therapy designation to abatacept for the prevention of moderate to severe acute graft-versus-host disease in hematopoietic stem cell transplants from unrelated donors.

Original Article: FDA Grants Breakthrough Therapy Designation to Abatacept for Acute GVHD Prevention

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Breakthrough Therapy Designation to Abatacept for Acute GVHD Prevention"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...